Several analysts have recently updated their ratings and price targets for Alexion Pharmaceuticals (NASDAQ: ALXN):

  • 8/5/2017 – Alexion Pharmaceuticals was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 8/2/2017 – Alexion Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $158.00 price target on the stock. According to Zacks, “Alexion reported better-than-expected results in the second quarter and concurrently raised its earnings and revenue guidance. Alexion’s blockbuster drug, Soliris, continues to perform well. A potential label expansion of the drug for additional indications will boost revenues. Among new products, while Strensiq is doing well, the company redefined its strategy for Kanuma which earlier lagged expectations. In order to focus better in core areas, Alexion is de-prioritizing a few clinical programs and terminating its partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma. We expect investor focus on results from the realignment of the resources and Kanuma's performance. Shares of the company have outperformed the industry so far in 2017. However, the company relies heavily on Soliris for growth while prcing will impact Strensiq revenues in the second half.”
  • 7/28/2017 – Alexion Pharmaceuticals had its price target raised by analysts at Leerink Swann from $136.00 to $170.00. They now have an “outperform” rating on the stock.
  • 7/28/2017 – Alexion Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $153.00 price target on the stock, up previously from $141.00.
  • 7/28/2017 – Alexion Pharmaceuticals was upgraded by analysts at Oppenheimer Holdings, Inc. from a “market perform” rating to an “outperform” rating. They now have a $175.00 price target on the stock.
  • 7/28/2017 – Alexion Pharmaceuticals had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $168.00 price target on the stock, up previously from $159.00.
  • 7/25/2017 – Alexion Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/14/2017 – Alexion Pharmaceuticals was upgraded by analysts at TheStreet from a “c” rating to a “b-” rating.
  • 7/14/2017 – Alexion Pharmaceuticals had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $165.00 price target on the stock.
  • 7/3/2017 – Alexion Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $122.00 price target on the stock.
  • 6/26/2017 – Alexion Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Robert W. Baird. They now have a $145.00 price target on the stock.
  • 6/26/2017 – Alexion Pharmaceuticals had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $142.00 price target on the stock, up previously from $140.00.
  • 6/22/2017 – Alexion Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Leerink Swann.
  • 6/20/2017 – Alexion Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 6/14/2017 – Alexion Pharmaceuticals was given a new $164.00 price target on by analysts at Credit Suisse Group. They now have a “buy” rating on the stock.
  • 6/14/2017 – Alexion Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $138.00 price target on the stock.
  • 6/14/2017 – Alexion Pharmaceuticals had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 6/14/2017 – Alexion Pharmaceuticals had its “hold” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 6/14/2017 – Alexion Pharmaceuticals had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $108.00 price target on the stock.
  • 6/13/2017 – Alexion Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down 3.32% on Thursday, reaching $132.30. The company had a trading volume of 1,748,492 shares. The firm has a market capitalization of $29.53 billion, a price-to-earnings ratio of 57.37 and a beta of 1.41. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $145.42. The firm has a 50-day moving average price of $128.92 and a 200 day moving average price of $122.85.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.48. The company had revenue of $912 million during the quarter, compared to the consensus estimate of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. Alexion Pharmaceuticals’s revenue was up 21.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.13 EPS. Equities research analysts predict that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current year.

In other news, CEO Ludwig Hantson acquired 10,000 shares of the company’s stock in a transaction dated Wednesday, June 14th. The stock was acquired at an average cost of $116.72 per share, for a total transaction of $1,167,200.00. Following the acquisition, the chief executive officer now directly owns 38,725 shares in the company, valued at approximately $4,519,982. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bros. Advisors Lp Baker acquired 1,348,955 shares of the company’s stock in a transaction dated Wednesday, June 14th. The shares were purchased at an average price of $116.32 per share, with a total value of $156,910,445.60. The disclosure for this purchase can be found here. Insiders acquired a total of 2,019,734 shares of company stock valued at $235,606,846 over the last quarter. 4.35% of the stock is currently owned by insiders.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.